NYSE:MNK - Mallinckrodt Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $9.87 -3.16 (-24.25 %) (As of 05/22/2019 06:43 AM ET)Previous Close$13.03Today's Range$8.45 - $9.9452-Week Range$8.45 - $36.65Volume17.10 million shsAverage Volume2.16 million shsMarket Capitalization$827.24 millionP/E Ratio1.23Dividend YieldN/ABeta2.12 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers H.P. Acthar Gel, an injectable drug for various indications, such as rheumatoid arthritis, multiple sclerosis, infantile spasms, systemic lupus erythematosus, polymyositis, and others; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; and Therakos photopheresis, an immunotherapy treatment platform. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; StrataGraft, which is in Phase III and II clinical development for the treatment of burns; Stannsoporfin, a heme oxygenase inhibitor for the treatment of jaundice; Xenon gas for inhalation; MNK-6105 and MNK-6106, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; VTS-270 that is in Phase III development for Niemann-Pick Type C, a neurodegenerative disease; and CPP-1X/sulindac, which is in Phase III development for Familial Adenomatous Polyposis. It markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. The company was founded in 1867 and is based in Staines-Upon-Thames, the United Kingdom. Receive MNK News and Ratings via Email Sign-up to receive the latest news and ratings for MNK and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:MNK Previous Symbol CUSIPN/A CIK1567892 Webhttp://www.mallinckrodt.com/ Phone44-0-17-8463-6700Debt Debt-to-Equity Ratio1.90 Current Ratio1.45 Quick Ratio1.08Price-To-Earnings Trailing P/E Ratio1.23 Forward P/E Ratio1.18 P/E Growth0.15 Sales & Book Value Annual Sales$3.22 billion Price / Sales0.26 Cash Flow$12.3375 per share Price / Cash Flow0.80 Book Value$36.44 per share Price / Book0.27Profitability EPS (Most Recent Fiscal Year)$8.01 Net Income$-3,607,000,000.00 Net Margins-118.53% Return on Equity14.22% Return on Assets5.26%Miscellaneous Employees3,700 Outstanding Shares83,814,000Market Cap$827.24 million Next Earnings Date8/6/2019 (Estimated) OptionableOptionable Mallinckrodt (NYSE:MNK) Frequently Asked Questions What is Mallinckrodt's stock symbol? Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK." How were Mallinckrodt's earnings last quarter? Mallinckrodt PLC (NYSE:MNK) released its quarterly earnings results on Tuesday, May, 7th. The company reported $1.94 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.73 by $0.21. The business earned $791 million during the quarter, compared to analysts' expectations of $766.27 million. Mallinckrodt had a positive return on equity of 14.22% and a negative net margin of 118.53%. The firm's revenue for the quarter was up 4.7% compared to the same quarter last year. During the same period last year, the firm posted $1.31 EPS. View Mallinckrodt's Earnings History. When is Mallinckrodt's next earnings date? Mallinckrodt is scheduled to release their next quarterly earnings announcement on Tuesday, August 6th 2019. View Earnings Estimates for Mallinckrodt. What guidance has Mallinckrodt issued on next quarter's earnings? Mallinckrodt issued an update on its FY19 earnings guidance on Tuesday, May, 7th. The company provided EPS guidance of $8.30-8.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.21. Mallinckrodt also updated its FY 2019 guidance to $8.30-8.60 EPS. What price target have analysts set for MNK? 15 Wall Street analysts have issued 1-year target prices for Mallinckrodt's shares. Their predictions range from $5.00 to $58.00. On average, they expect Mallinckrodt's stock price to reach $29.8667 in the next twelve months. This suggests a possible upside of 202.6% from the stock's current price. View Analyst Price Targets for Mallinckrodt. What is the consensus analysts' recommendation for Mallinckrodt? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mallinckrodt in the last year. There are currently 3 sell ratings, 8 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Mallinckrodt. What are Wall Street analysts saying about Mallinckrodt stock? Here are some recent quotes from research analysts about Mallinckrodt stock: 1. According to Zacks Investment Research, "Mallinckrodt’s hospital franchise (Inomax and Ofirmev) has gained traction which is positively impacting performance. The spin-off of the generic business appears to be a step in the right direction as this will enable Mallinckrodt to focus better on the branded business, which promises potential. Mallinckrodt has streamlined its business of late to focus better on its innovative medicines and therapies. The company has been involved in quite a few lawsuits for its alleged role in the current opioid epidemic in the United States through its marketing and promotion practices. Shares have outperformed the industry in the last six months. However, pipeline setbacks continue to weigh on the company. The CRL for stannsoporfin was disappointing. Acthar, Mallinckrodt’s largest product, is being impacted by the residual impact of the previously reported patient withdrawal issues." (1/8/2019) 2. Mizuho analysts commented, "We reiterate our Neutral rating into what we view as risky read-outs for VTS-270 in Niemann- Pick Type C, and CPP-1X/Sulindac in FAP." (11/6/2018) 3. Canaccord Genuity analysts commented, "We were pleasantly surprised by Mallinckrodt’s 2Q/18 beat and raise last week as the story continues to evolve toward higher pipeline science and away from Acthar- related drama. However, with strong momentum behind MNK shares of late, we remain concerned about external forces on Acthar or internal pipeline setbacks potentially squelching momentum in the story." (8/13/2018) Has Mallinckrodt been receiving favorable news coverage? News coverage about MNK stock has been trending somewhat negative recently, InfoTrie reports. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Mallinckrodt earned a coverage optimism score of -1.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. Who are some of Mallinckrodt's key competitors? Some companies that are related to Mallinckrodt include Array Biopharma (ARRY), Horizon Therapeutics (HZNP), TESARO (TSRO), United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Alkermes (ALKS), American Brivision (Holding) (ABVC), Evotec (EVTCY), Blueprint Medicines (BPMC), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), FibroGen (FGEN) and Agios Pharmaceuticals (AGIO). What other stocks do shareholders of Mallinckrodt own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mallinckrodt investors own include Gilead Sciences (GILD), Micron Technology (MU), Bausch Health Companies (BHC), Gerdau (GGB), Celgene (CELG), Teva Pharmaceutical Industries (TEVA), Skyworks Solutions (SWKS), Alibaba Group (BABA), AT&T (T) and Biogen (BIIB). Who are Mallinckrodt's key executives? Mallinckrodt's management team includes the folowing people: Mr. Mark Christopher Trudeau, Pres, CEO & Director (Age 58)Dr. Frank Scholz, Exec. VP and Chief Operations & Digital Innovation Officer (Age 50)Mr. Matthew K. Harbaugh, Exec. VP & Pres of Specialty Generics (Age 49)Mr. Hugh M. O'Neill, Exec. VP & Chief Commercial Officer (Age 56)Mr. Bryan M. Reasons, Chief Financial Officer (Age 52) Who are Mallinckrodt's major shareholders? Mallinckrodt's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (11.85%), Dimensional Fund Advisors LP (8.34%), LSV Asset Management (4.97%), AQR Capital Management LLC (2.81%), MERIAN GLOBAL INVESTORS UK Ltd (2.61%) and Northern Trust Corp (2.10%). Company insiders that own Mallinckrodt stock include Coleman N Lannum III, David R Carlucci, Dr Kneeland Youngblood, Hugh M O'neill, James E Flynn, Joann A Reed, Mark Trudeau, Meredith B Fischer, Michael-Bryant Hicks and Steven J Romano. View Institutional Ownership Trends for Mallinckrodt. Which institutional investors are selling Mallinckrodt stock? MNK stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Robeco Institutional Asset Management B.V., Renaissance Technologies LLC, Spark Investment Management LLC, BlackRock Inc., Acadian Asset Management LLC, Royce & Associates LP and SG Americas Securities LLC. View Insider Buying and Selling for Mallinckrodt. Which institutional investors are buying Mallinckrodt stock? MNK stock was purchased by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Dimensional Fund Advisors LP, Wells Fargo & Company MN, Hussman Strategic Advisors Inc., Bank of Montreal Can, 361 Capital LLC, Geode Capital Management LLC and Parametric Portfolio Associates LLC. Company insiders that have bought Mallinckrodt stock in the last two years include Coleman N Lannum III, David R Carlucci, Dr Kneeland Youngblood, Hugh M O'neill, Joann A Reed, Mark Trudeau, Meredith B Fischer, Michael-Bryant Hicks and Steven J Romano. View Insider Buying and Selling for Mallinckrodt. How do I buy shares of Mallinckrodt? Shares of MNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Mallinckrodt's stock price today? One share of MNK stock can currently be purchased for approximately $9.87. How big of a company is Mallinckrodt? Mallinckrodt has a market capitalization of $827.24 million and generates $3.22 billion in revenue each year. The company earns $-3,607,000,000.00 in net income (profit) each year or $8.01 on an earnings per share basis. Mallinckrodt employs 3,700 workers across the globe. What is Mallinckrodt's official website? The official website for Mallinckrodt is http://www.mallinckrodt.com/. How can I contact Mallinckrodt? Mallinckrodt's mailing address is 3 LOTUS PARK THE CAUSEWAY STAINES-UPON-THAMES, SURREY X0, TW18 3AG. The company can be reached via phone at 44-0-17-8463-6700 or via email at [email protected] MarketBeat Community Rating for Mallinckrodt (NYSE MNK)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 745 (Vote Outperform)Underperform Votes: 513 (Vote Underperform)Total Votes: 1,258MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt and other stocks. Vote "Outperform" if you believe MNK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: What is a stock buyback? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.